Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T H 1 T cells

References

• Fialkow PJ, Jacobson RJ, Papayannopoulou T Chronic mye- locytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/ macrophage. Am y Med 1997;63:125–30.
   Google Scholar
• Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132: 1497–99.
   Web of Science ®Google Scholar
• Rowley JD. A new consistent chromosomal abnormality inchronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973;243:290–93.
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A et al. Translocationof c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277–80.
   PubMedGoogle Scholar
• Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused tran-script of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550–54.
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. 7 Chn Invest 1998;101:2290–96.
   PubMed Web of Science ®Google Scholar
• Mannering SI, McKenzie JL, Fearnley DB, Hart DNJ. HLA-DR1 -restricted bcr-abl (b3a2)-specific C D4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997;90:290–97.
   PubMed Web of Science ®Google Scholar
• MacIntyre AR, Christmas SE, Clark RE. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol 1996;24:1307–11.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.
   PubMed Web of Science ®Google Scholar
• Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leukemia Lymphoma 1993;10:427–37.
   PubMed Web of Science ®Google Scholar
• Eibl B, Ebner S, Duba C et al Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997;20:215–23.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Gajewski JL, Liang JC et al Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133–42.
   PubMed Web of Science ®Google Scholar
• Smit WM, Rijnbeek M, van Bergen CAM et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Human Immunol 1997;53:216–23.
   Google Scholar
• Fujii S, Shimizu K, Fujimoto K et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. YpnY Cancer Res 1999;90:1117–29.
   Google Scholar
• Cervantes F, Pierson BA, McGlave PB et al Autologous acti-vated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996;87:2476–85.
   PubMed Web of Science ®Google Scholar
• Krackhardt A, Maurer J, Thiel E, Notter M. Activation of autologous lymphocytes of patients with chronic myeloge-nous leukemia in the chronic phase with cytokines and CD3 monoclonal antibody results in bcr/abl- blood leukocyte cultures as determined by reverse transcriptase-polymerase chain reaction. Exp Hematol 1998;26:1265–70.
   Google Scholar
• Hoyle C, Bangs CD, Chang P et al. Expansion of Philadelphia chromosome-negative CD3±CD56+ cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency dis-ease mice. Blood 1998;92:3318–27.
   PubMed Web of Science ®Google Scholar
• Varadi G, Ackerstein A, Ben-Neriah S, Nagler A. Adoptive cell-mediated immunotherapy with interlukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myel-ogenous leukemia patient. Bone Marrow Transplant 1998;21: 93–96.
   Google Scholar
• Lonnqvist B, Brune M, Ljungman P. Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML — a case report. Bone Marrow Transplant 1996;18: 241–42.
   Google Scholar
• Goodman M, Spector N, Rodrigues G, Cassileth PA. Interleukin-2 therapy for advanced chronic myeloid leukemia. Leukemia 1998;12:1682–84.
   PubMed Web of Science ®Google Scholar
• Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leukemia Lymphoma 1997;27:387–99.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Vuk-Pavlovi S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91:392–98.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Bulur PA, Erickson MR et al. Optimizing prepar-ation of normal dendritic cells and bcr-abl positive mature dendritic cells derived from immunomagnetically purified CD14 positive cells. 7 Hematotherapy Stem Cell Res 2000;9: 95–101.
   Google Scholar
• Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur 7 Immunol 1997;27: 3135–42.
   Google Scholar
• Hilkens CM, Kalinski P, de Boer B, Kapsenberg M. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Thl phenotype. Blood 1997;90:1920–26.
   PubMed Web of Science ®Google Scholar
• Heufler C, Kalinski P, de Boer B, Kapsenberg M. Interleukin-12 is produced by dendritic cell and mediates T helper 1 development as well as interferon-I production by T cells. Eur y Immunol 1996;26:659–68.
   PubMed Web of Science ®Google Scholar
• Labeur MS, Roters B, Pers B et al. Generation of tumor immunity by bone marrow-derived dendritic cells correl-ates with dendritic cell maturation stage. 7 Immunol 1999;162:168–75.
   PubMed Web of Science ®Google Scholar
• Addison CL, Bramson JL, Hitt MM et al. Intratumoral coin-jection of adenovirual vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998;5:1400–09 .
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fields RC, Giedlin M, Mulep. Systemic admin-istration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999;96:2268–73.
   PubMed Web of Science ®Google Scholar
• Brossart P, Goldrath AW, Butz EA et al. Virus-mediated delivery of antigenic epitopes in dendritic cells as a means to induce CT L. 7 Immunol1997;158: 3270–76.
   Google Scholar
• Molnar-Kimber KL, Sterman DH, Chang M et al Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clin-ical trial for localized mesothelioma. Human Gene Therapy 1998;9:2121–33.
   PubMed Web of Science ®Google Scholar
• Ranieri E, Herr W, Gambotto A et al. Dendritic cells trans-fected with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vac-cination. 7 Viro/ 1999;73:10416–25.
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56–68.
   PubMed Web of Science ®Google Scholar